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During capsid assembly of bacteriophage P2 and its satellite phage P4, gpN undergoes proteolytic cleavage with the
removal of the first 31 amino acids. The truncated protein gpN* is unable to support formation of viable phages in complemen-
tation tests. A c-myc antigenic epitope (EQKLISEEDL) exchanged for eleven amino acids in the amino terminal part of gpN
results in both proteolytic processing of gpN: :c-myc as well as assembly of P2 and P4 procapsid-like structures, but gpN: :c-
myc failed, like N*, to support the production of infectious P2 and P4 particles. q 1996 Academic Press, Inc.
P2 and P4 are temperate phages that infect Esche- of viable phages as well as the tolerance of amino acid
replacements in the region between h2 and N* for virusrichia coli (1). P4 lacks the genetic information for its
structural proteins and relies upon its ability to control production. Tolerance of amino acid replacements in this
portion of the N protein might be exploited for peptidethe late genes of P2, its helper (2, 3), which codes for
the head and tail proteins. P4 encodes, however, a cap- presentation by P4 (10, 11).
To test the ability of N* to complement gpN in makingsid-size determination protein called Sid. This protein
directs the formation of the P4 capsid (T  4), which is infectious P2 and P4 particles, burst-size experiments
were performed with a temperature sensitive P2 N mu-smaller than that of phage P2 (T  7) (4). The P4 capsid
fits the 11.6-kbp genome of P4, while the P2 capsid ac- tant (P2 sir22, nonpermissive temperature is 377, pro-
vided by E. Six). The N*-protein was also tested for itscommodates the 33.8-kbp P2 genome (5). The capsid
protein gpN (357 aa), which we focus on in this communi- ability to complement P4 particle formation, monitored in
a P4-P2 sir22 coinfection. The N* part of the N gene wascation, is processed into three products: the major head
protein N* (31 amino acids cleaved from the amino termi- cloned into a pBluescript II-vector and transformed into
the standard host for P2 and P4 (E. coli C1-a (12)) fornal) and the minor head proteins h1 and h2, where 9
burst-size experiments. A full-length N gene clone wasand 13 amino acids, respectively, are removed from the
constructed in the same way as the N* clone and usedamino terminal gpN (Fig. 1) (6, 7). The mature P2 capsid
as control. In C1-a, N as well as N* show moderateconsists of 420 N* subunits, whereas that of P4 contains
constitutive expression from the lac promoter of the20 h1 and 40 h2 in addition to 180 subunits of N* (7).
pBluescript vector (results not shown). The results of theThe capsid assembly properties of N and N* have been
complementation tests for P2 and P4 are shown in Tableanalyzed in cells expressing a cloned N gene or a de-
1. They demonstrate that N expression is able to comple-leted version of the N gene giving rise to N* directly. In
ment P2 sir22 at 377 as well as to sustain P4 growth,both cases P2- and P4-size procapsid structures were
while N* expression fails to support either P2 sir22 orobserved by electron microscopy (8, 9). This finding im-
P4 growth. This result indicates that the 31-amino acidplies that the amino-terminal part (31 amino acids) of
region preceding the cleavage site giving rise to N* isgpN is not required for assembly initiation (9). It was not
essential for making infectious P2 as well as P4 particles.determined, however, whether N* was able to support
As procapsid-like structures can assemble from N*-the formation of viable phage particles. In this communi-
monomers (9), it appears that the N-terminal part of gpNcation we test the ability of N* to support the formation
is required during the postassembly maturation pro-
cesses of the capsid rather than the initiation of procap-1 Present address: Department of Molecular and Cell Biology, Univer-
sid assembly itself. If cleavage of N preceded initial as-sity of California at Berkeley, CA 94720.
sembly, we would expect N* to assemble into infectious2 To whom correspondence and reprint requests should be ad-
dressed. Fax: /47 22 69 41 30. E-mail: bjorn.lindqvist@bio.uio.no. particles. Since the opposite is observed, cleavage of
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FIG. 1. An outline of the cleavage sites at the amino terminal part of gpN (7) and the c-myc sequence exchange between the h2 and N* cleavage
sites.
N most likely occurs after prohead assembly. This is sence and presence of gpSid (supplied by infection
with P4 vir1). Oligomeric structures were isolated fromconsistent with the observation that immature procap-
sids isolated from a mixed infection with P2 and P4 also the cell debris by differential centrifugation and puri-
fied by equilibrium centrifugation in a CsCl densitycontain full-length N (9).
To further investigate the dependence on the N-termi- gradient. The structures obtained from the N : : c-myc
expressing cells were predominantly large aggre-nal region of gpN in P2 and P4 particle maturation and
to explore the possibility of using this region for peptide gates and aberrant unclosed shells, but there were
also a fraction of closed shells of varying sizes rangingdisplay by P4, a 33-bp replacement was made between
the nucleotides corresponding to the h2 and N* cleavage from about 40 to 60 nm (Figs. 2A and 2B). The known
dimensions of P2 and P4 procapsids, 55 and 40 nm,sites (see Fig. 1). This was done by site-specific muta-
genesis according to Kunkel et al. (13). The new amino respectively, fit within this size range. Hence, the re-
sult indicates that the N : : c-myc protein is able to formacid sequence corresponds to the first 10 amino acids
of the human p62 c-myc protein followed by a proline closed procapsid-like structures of both P2 and P4
sizes, comparable to the structures obtained from theresidue. This insertion results in a 10 amino acid c-myc
epitope (EQKLISEEDL) that is specifically recognized by N or N* expressing cells (8, 9). In the case where
N : : c-myc was expressed in the presence of gpSid, wethe murine monoclonal antibody, c-myc Tag 1. The pro-
cessing and assembly properties of N: :c-myc as well as observed an increase in the number of closed shells
with an average size of 40 – 45 nm (Fig. 2B). Hence,the ability to support the production of infectious P2 or
P4 particles in complementation tests were studied in N : : c-myc appears to be able to respond to the size-
directing effect of gpSid. As the processing of gpN isC1-a cells. The pBluescriptII/N : :c-myc construction, de-
noted pKB3, is identical to the N-expressing clone pOM3 part of the capsid maturation, it was also of interest
to determine whether N : : c-myc could be processed(8), except for the c-myc sequence. pOM3 was used as
a control in all experiments. into h1, h2, and N*. In order to investigate the extent of
processing, the purified oligomeric structures of N : : c-The gpN : : c-myc protein was analyzed for its ability
to assemble into procapsid-like structures in the ab- myc (//0 gpSid) were immunodetected by polyclonal
TABLE 1
Burst Size of P2 sir22 and P4 Obtained by Complementing with N* at Nonpermissive Temperature in C1-a
Burst sizea % of Burst size of % of Burst size of % of
Clone in C1-a of P2 sir22 307 P4b 307 P2 sir22c 307
pKB1 (N), 377 56 107 2 7 30 55
pKB2 (N*), 377 0.006 0.01 0.01 0.04 0.002 0.004
pBluescript II, 377 0.005 0.01 0.02 0.07 0.02 0.04
pBluescript II, 307 52 100 28 100 55 100
Note. Identical results were obtained when using E. coli XL1-Blue (13) as the host (results not shown).
a The burst size is a measure of the number of phages produced per infected cell. (Burst size  pfu observed/infective centers). Bacteria with
the appropriate Bluescript clone were grown in 10 ml LB containing 50 mg/ml Amp, 0.11% glucose, 2.5 mM CaCl2 at 307C or 377C to an optical
density of 0.2 (106 – 107 cells/ml) at 600 nm. Cells were collected by centrifugation and the pellet was resuspended in 2 ml of ice cold LB including
5 mM CaCl2 . Aliquots were plated to determine the cell count. 0.5 ml cells were transferred to a glass tube in a 377C water bath for the
complementation test and another at 307C for the control. The cells were infected with P2 sir22 at a multiplicity of infection of 4–6 at t  0.
Adsorption was allowed to proceed for 8 minutes, at which time P2-P4 antiserum was added to inactivate unabsorbed phages. The incubation was
continued for 10 minutes and then aliquots were taken to measure infective centers. After 18 minutes, the culture was serially diluted 106 –107 fold
into LB-containing glass tubes standing in the water bath, and incubation was continued. 90 minutes after infection, aliquots from different dilutions
were plated to determine the phage yield. Burst sizes were calculated by dividing the total burst by the number of infective centers.
b A co-infection with P4 vir1 (15) and P2 sir22 was performed to measure the complementation ability of N* to make infectious P4.
c Burst size of P2 sir22 was also measured in the co-infection experiment.
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FIG. 2. (A and B) Electron micrographs of capsid-related particles built up of N: :c-myc protein (pKB3). The CsCl-purified particles were prepared
for EM by negative staining with 1% PTA. The magnification was 80,0001: (A) particles of gpN: :c-myc, mainly ‘‘monsters’’ are produced (see
arrowhead), but also some closed structures (see arrow). (B) particles of gpN: :c-myc supplied with gpSid. Several closed particles are produced
with a size preference of 40– 45 nm (short arrow), but also some 55–60 nm wide (long arrow). (C) Size distribution of capsid-related particles
obtained by measuring 45 closed shells from the electron micrographs A and B. Series 1, N: :c-myc alone; series 2, N: :c-myc supplied with gpSid.
antibodies against N* (Fig. 3, lanes 2 – 4). The novel must be either autocatalytic or host-dependent as no
other P2 proteins are present under these experimen-amino acid sequence between the h2 and N* cleavage
sites does not seem to affect the processing of the tal conditions. The particle preparations were also an-
alyzed for the presence of the c-myc epitope by mono-N : : c-myc protein, when compared to the processing
observed in the mature P4 phage preparation (Fig. 3, clonal antibody Tag-1 after SDS – PAGE followed by
blotting the proteins onto a filter. The filter with dupli-lane 1). As noted before (8), the processing of gpN
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TABLE 2
Burst Size of P2 sir22 and P4 vir1 Obtained by Complementing with Nøc-myc at Nonpermissive Temperature in C1-a
Burst sizea Burst size of Burst size of
Clone in C1-a of P2 sir22 % of 307 P4b % of 307 P2 sir22c % of 307
pOM3, (N), 377 154 127 33 660 32 93
pKB3 (Nøc-myc), 377 0.02 0.016 0.07 1.4 0.003 0.009
pBluescriptII, 377 0.02 0.016 0.07 1.4 0.005 0.014
pBluescriptII, 307 121 100 5 100 35 100
Note. Refer to Table 1 footnotes.
cate samples was cut in two parts. The left part was formed as described for N*. Burst size results for P2 sir22
obtained from C1-a cells (Table 2) show that the N : :c-analyzed by polyclonal antibodies against N* (as al-
ready mentioned) and the right part by monoclonal myc clone (pKB3) fails to complement the tsN mutant
phage P2 sir22 at nonpermissive temperature (377), whileantibodies against c-myc. The results in Fig. 3 demon-
strate, as expected, that antibodies against c-myc the control (pOM3) complements P2 sir22 at the nonper-
missive temperature. This result demonstrates that N: :c-(lane 5 and 6) detect both full-length N : : c-myc and
h1 : : c-myc/h2 : : c-myc proteins, but not N*. Surpris- myc fusion protein is defective in supporting production
of infectious P2 in C1-a. Due to the possibility of usingingly, full-length N : : c-myc protein was detected to a
much lower extent compared to the strong detection the h1-h2 portion of gpN for peptide presentation by P4,
it was of special interest to test whether N : :c-myc couldof h1 : : c-myc/h2 : : c-myc proteins, even though the
amount of protein of N : : c-myc is larger than that of support growth of P4. Complementation tests were per-
formed as described for N* by coinfecting P2 sir22 andh1 : : c-myc/h2 : : c-myc (see Lanes 2, 3, and 4). The ac-
cess of monoclonal anti c-myc antibodies to the c-myc P4 vir1 in C1-a cells carrying the different N constructs.
The results in Table 2 show, however, that N: :c-myc isepitope appears reduced. Since we can detect h1 : : c-
myc and h2 : : c-myc proteins (we have not analyzed defective in sustaining P4 vir1 growth as well as produc-
tion of infectious P2 sir22 phage particles. Thus, thethem individually) with the antibodies, the extra amino
acids in front of the h1- or h2-cleavage sites must be amino terminal part of the capsid protein N appears nec-
essary to make infectious P2 and P4 virions. The N*responsible for the effect observed. This property has
apparently no effect on the cleavage of gpN : : c-myc version is not able to support infectious particles even
though N* can assemble into procapsid like particles (9).protein.
To test whether N: :c-myc can complement P2 sir22 N::c-myc can assemble into P2 and P4 sized procapsid
structures and undergo processing, but the final matura-and sustain P4 growth, complementation tests were per-
tion process into infectious particles appears defective.
In the case of N: :c-myc, capsid maturation is blocked
by the change of eight amino acids in the amino terminal
part of N (see Fig. 1). N* and N: :c-myc may block capsid
maturation at different stages of the process. It is possi-
ble that the P2 capsid scaffold, gpO, normally interacts
with the first 31 amino acids of gpN. gpO would then fail
to function if the h1-h2 region is altered or gone. Another
possible role for h1/h2 is to accommodate the portal
protein gpQ in the initial assembly process and/or in
DNA packaging.
FIG. 3. A Western blot of capsid-related structures made of gpN: :c-
myc detected by monoclonal c-myc antibodies and polyclonal N* anti-
bodies. CsCl-banded procapsid like structures from N : :c-myc express-
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